Spot On CML Grows in the Philippines

Spot On CML Grows in the Philippines

In 2017, The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) embarked on a groundbreaking collaboration to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries.

The collaboration is called Spot On CML and utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.

Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

The patients, the treating physicians at Philippine General, and the team at The Max Foundation all offer their heartfelt gratitude to Fred Hutch for this wonderful collaboration.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.

  • It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    Read the interview with the Nepal Live Today – October 21, 2024.

  • CMLPath to Care

    CMLPath to Care

    In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.